Logo image of XPEV

XPENG INC - ADR (XPEV) Stock Fundamental Analysis

USA - NYSE:XPEV - US98422D1054 - ADR

25.01 USD
-1.37 (-5.19%)
Last: 11/14/2025, 8:04:00 PM
25.05 USD
+0.04 (+0.16%)
After Hours: 11/14/2025, 8:04:00 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to XPEV. XPEV was compared to 36 industry peers in the Automobiles industry. The financial health of XPEV is average, but there are quite some concerns on its profitability. XPEV is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

XPEV had negative earnings in the past year.
In the past year XPEV had a positive cash flow from operations.
In the past 5 years XPEV always reported negative net income.
In the past 5 years XPEV reported 4 times negative operating cash flow.
XPEV Yearly Net Income VS EBIT VS OCF VS FCFXPEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -2B -4B -6B -8B -10B

1.2 Ratios

XPEV's Return On Assets of -4.63% is fine compared to the rest of the industry. XPEV outperforms 69.44% of its industry peers.
With a decent Return On Equity value of -14.11%, XPEV is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
ROA -4.63%
ROE -14.11%
ROIC N/A
ROA(3y)-10.7%
ROA(5y)-10.09%
ROE(3y)-23.94%
ROE(5y)-19.52%
ROIC(3y)N/A
ROIC(5y)N/A
XPEV Yearly ROA, ROE, ROICXPEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

With a decent Gross Margin value of 16.36%, XPEV is doing good in the industry, outperforming 66.67% of the companies in the same industry.
XPEV's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for XPEV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.05%
GM growth 5YN/A
XPEV Yearly Profit, Operating, Gross MarginsXPEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

4

2. Health

2.1 Basic Checks

XPEV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XPEV has more shares outstanding
XPEV has more shares outstanding than it did 5 years ago.
XPEV has a worse debt/assets ratio than last year.
XPEV Yearly Shares OutstandingXPEV Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
XPEV Yearly Total Debt VS Total AssetsXPEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

Based on the Altman-Z score of 1.55, we must say that XPEV is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of XPEV (1.55) is better than 66.67% of its industry peers.
The Debt to FCF ratio of XPEV is 2.65, which is a good value as it means it would take XPEV, 2.65 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.65, XPEV belongs to the top of the industry, outperforming 86.11% of the companies in the same industry.
XPEV has a Debt/Equity ratio of 0.78. This is a neutral value indicating XPEV is somewhat dependend on debt financing.
XPEV has a Debt to Equity ratio (0.78) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 2.65
Altman-Z 1.55
ROIC/WACCN/A
WACC7.5%
XPEV Yearly LT Debt VS Equity VS FCFXPEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B 30B 40B

2.3 Liquidity

XPEV has a Current Ratio of 1.14. This is a normal value and indicates that XPEV is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of XPEV (1.14) is comparable to the rest of the industry.
XPEV has a Quick Ratio of 1.00. This is a normal value and indicates that XPEV is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.00, XPEV is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1
XPEV Yearly Current Assets VS Current LiabilitesXPEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.92% over the past year.
Looking at the last year, XPEV shows a very strong growth in Revenue. The Revenue has grown by 66.37%.
The Revenue has been growing by 77.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)48.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.24%
Revenue 1Y (TTM)66.37%
Revenue growth 3Y24.87%
Revenue growth 5Y77.48%
Sales Q2Q%125.29%

3.2 Future

XPEV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.29% yearly.
XPEV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.79% yearly.
EPS Next Y76.93%
EPS Next 2Y50.26%
EPS Next 3Y38.71%
EPS Next 5Y23.29%
Revenue Next Year94.98%
Revenue Next 2Y64.92%
Revenue Next 3Y46.01%
Revenue Next 5Y30.79%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
XPEV Yearly Revenue VS EstimatesXPEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50B 100B 150B 200B
XPEV Yearly EPS VS EstimatesXPEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10

3

4. Valuation

4.1 Price/Earnings Ratio

XPEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 112.73, the valuation of XPEV can be described as expensive.
63.89% of the companies in the same industry are more expensive than XPEV, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of XPEV to the average of the S&P500 Index (34.59), we can say XPEV is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 112.73
XPEV Price Earnings VS Forward Price EarningsXPEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

XPEV's Price/Free Cash Flow ratio is rather cheap when compared to the industry. XPEV is cheaper than 83.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.54
EV/EBITDA N/A
XPEV Per share dataXPEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as XPEV's earnings are expected to grow with 38.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.26%
EPS Next 3Y38.71%

0

5. Dividend

5.1 Amount

No dividends for XPEV!.
Industry RankSector Rank
Dividend Yield N/A

XPENG INC - ADR

NYSE:XPEV (11/14/2025, 8:04:00 PM)

After market: 25.05 +0.04 (+0.16%)

25.01

-1.37 (-5.19%)

Chartmill FA Rating
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobiles
Earnings (Last)08-19 2025-08-19/bmo
Earnings (Next)11-17 2025-11-17/bmo
Inst Owners14.4%
Inst Owner Change-4.74%
Ins Owners0.25%
Ins Owner ChangeN/A
Market Cap23.84B
Revenue(TTM)60.29B
Net Income(TTM)-4.28B
Analysts78.18
Price Target25.96 (3.8%)
Short Float %10.02%
Short Ratio4.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.32%
Min EPS beat(2)34.81%
Max EPS beat(2)47.83%
EPS beat(4)2
Avg EPS beat(4)18.11%
Min EPS beat(4)-8.69%
Max EPS beat(4)47.83%
EPS beat(8)4
Avg EPS beat(8)16.95%
EPS beat(12)4
Avg EPS beat(12)3.67%
EPS beat(16)6
Avg EPS beat(16)-1.04%
Revenue beat(2)1
Avg Revenue beat(2)-0.37%
Min Revenue beat(2)-3.26%
Max Revenue beat(2)2.52%
Revenue beat(4)2
Avg Revenue beat(4)-0.21%
Min Revenue beat(4)-3.26%
Max Revenue beat(4)2.52%
Revenue beat(8)2
Avg Revenue beat(8)-2.74%
Revenue beat(12)2
Avg Revenue beat(12)-5.64%
Revenue beat(16)5
Avg Revenue beat(16)-2.91%
PT rev (1m)0.66%
PT rev (3m)3.84%
EPS NQ rev (1m)-5.6%
EPS NQ rev (3m)32.74%
EPS NY rev (1m)1.91%
EPS NY rev (3m)14.06%
Revenue NQ rev (1m)-0.79%
Revenue NQ rev (3m)-3.31%
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)-0.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 112.73
P/S 2.81
P/FCF 16.54
P/OCF 12.99
P/B 5.58
P/tB 6.51
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)0.22
Fwd EY0.89%
FCF(TTM)1.51
FCFY6.05%
OCF(TTM)1.92
OCFY7.7%
SpS8.92
BVpS4.49
TBVpS3.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.63%
ROE -14.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.36%
FCFM 16.96%
ROA(3y)-10.7%
ROA(5y)-10.09%
ROE(3y)-23.94%
ROE(5y)-19.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.05%
GM growth 5YN/A
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 2.65
Debt/EBITDA N/A
Cap/Depr 104.83%
Cap/Sales 4.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 1
Altman-Z 1.55
F-Score6
WACC7.5%
ROIC/WACCN/A
Cap/Depr(3y)220.74%
Cap/Depr(5y)357.27%
Cap/Sales(3y)10.3%
Cap/Sales(5y)14.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.24%
EPS Next Y76.93%
EPS Next 2Y50.26%
EPS Next 3Y38.71%
EPS Next 5Y23.29%
Revenue 1Y (TTM)66.37%
Revenue growth 3Y24.87%
Revenue growth 5Y77.48%
Sales Q2Q%125.29%
Revenue Next Year94.98%
Revenue Next 2Y64.92%
Revenue Next 3Y46.01%
Revenue Next 5Y30.79%
EBIT growth 1Y26.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year90.09%
EBIT Next 3Y43.32%
EBIT Next 5Y30.46%
FCF growth 1Y-227.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-310.46%
OCF growth 3YN/A
OCF growth 5YN/A

XPENG INC - ADR / XPEV FAQ

Can you provide the ChartMill fundamental rating for XPENG INC - ADR?

ChartMill assigns a fundamental rating of 4 / 10 to XPEV.


Can you provide the valuation status for XPENG INC - ADR?

ChartMill assigns a valuation rating of 3 / 10 to XPENG INC - ADR (XPEV). This can be considered as Overvalued.


Can you provide the profitability details for XPENG INC - ADR?

XPENG INC - ADR (XPEV) has a profitability rating of 2 / 10.